Risk factors for severe respiratory syncytial virus infection during the first year of life: development and validation of a clinical prediction model
Authors:
- Pekka VartiainenPVPekka Vartiainen
- Sakari JukarainenSJSakari Jukarainen
- Samuel Arthur RhedinSRSamuel Arthur Rhedin
- Tuomo HartonenTHTuomo Hartonen
- Andrius VabalasAVAndrius Vabalas
- Essi ViippolaEVEssi Viippola
- Rodosthenis S. RodosthenousRRRodosthenis S. Rodosthenous
- Sara KuitunenSKSara Kuitunen
- Aoxing LiuALAoxing Liu
- Cecilia LundholmCLCecilia Lundholm
- Awad I. SmewASAwad I. Smew
Preprint
Abstract
Background Novel immunisation methods against respiratory syncytial virus (RSV) are emerging, but knowledge of risk factors for severe RSV disease is insufficient for their optimal targeting. We aimed to identify predictors for RSV hospitalisation, and to develop and validate a clinical prediction model to guide RSV immunoprophylaxis for under 1-year-old infants. Methods In this retrospective cohort study using nationwide registries, we studied all infants born in 1997-2020 in Finland (n = 1 254 913) and in 2006-2020 in Sweden (n = 1 459 472), and their parents and siblings. We screened 1 510 candidate predictors and we created a logistic regression model with 16 predictors and compared its performance to a machine learning model (XGboost) using all 1 510 candidate predictors. Findings In addition to known predictors such as severe congenital heart defects (CHD, adjusted odds ratio (aOR) 2·89, 95% confidence interval 2·28-3·65), we identified novel predictors for RSVH, most notably esophageal malformations (aOR 3·11, 1·86-5·19) and lower complexity CHDs (aOR 1·43, 1·25-1·63). In validation data from 2018-2020, the C-statistic was 0·766 (0·742-0·789) in Finland and 0·737 (0·710-0·762) in Sweden. The clinical prediction model’s performance was similar to the machine learning model (C-statistic in Finland 0·771, 0·754-0·788). Calibration varied according to epidemic intensity. Model performance was similar across different strata of parental income. The infants in the 90th percentile of predicted RSVH probability hospitalisation had 3·3 times higher observed risk than the population’s average. Assuming 60% effectiveness, immunisation in this top 10% of infants at highest risk would have a number needed to treat of 23 in Finland and 40 in Sweden in preventing hospitalisations. Interpretation The identified predictors and the prediction model can be used in guiding RSV immunoprophylaxis in infants. Funding Sigrid Jusélius Foundation, European Research Council, Pediatric Research Foundation (for complete list of funding sources, see Acknowledgements).Keywords
All Related Versions
- Published version: The Lancet Digital Health, 5 (11), e821.
This publication has 38 references indexed in Scilit:
- Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trialsThe Lancet Child & Adolescent Health, 2023
- Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort studyThe Lancet Child & Adolescent Health, 2023
- Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysisThe Lancet, 2022
- Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling studyThe Lancet Infectious Diseases, 2021
- Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in InfantsNew England Journal of Medicine, 2020
- Pneumonia after Repair of Esophageal Atresia–Incidence and Main Risk FactorsEuropean Journal of Pediatric Surgery, 2018
- Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for EnglandThe Lancet Public Health, 2017
- Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic DiseasesInfectious Diseases and Therapy, 2017
- Characterizing the risk of respiratory syncytial virus in infants with older siblings: a population-based birth cohort studyEpidemiology and Infection, 2016
- Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart DiseaseInfectious Diseases and Therapy, 2016